Achaogen is a biopharmaceutical company focused on developing innovative antibiotics to combat resistant infections. With its lead product, ZEMDRI® (plazomicin), Achaogen aims to address urgent medical needs in treating complicated urinary tract infections, emphasizing safety, efficacy, and accessibility in the biotechnology and life sciences sectors.
Madrid, • Spain
Wien, • Austria
Massachusetts, • United States
Upper Garonne, • France • Healthcare Technology
Antibacterial resistance-breakers, Drug-resistant infection treatments, Clinical-stage biopharmaceuticals, Targeting WHO priority pathogens, Innovative therapeutic solutions
Yerushalayim, • Israel